Press release
Global Alzheimer’s Disease Drugs Market, Regional Analysis & Forecast, Major Deals & Funding, and Pipeline Drugs Analysis to 2021
Alzheimer’s disease is the most common cause of dementia among older people. It is a devastating condition for those afflicted as well as their family members and caregivers; the situation is only getting worse as the population ages. With the ageing global population, the number of patients suffering from Alzheimer’s disease is predicted to grow during the forecasting period. Alzheimer's treatment is a high risk, high reward market. Drugs currently available in the market have reached maturity; patent of leading drugs have expired. The current unmet needs represent a huge opportunity for pharmaceutical companies which are developing targeted novel therapies.
Global Alzheimer’s Disease Drugs Market and Pipeline Drugs Analysis
• In 2016, the global market for Alzheimer’s disease drugs was dominated by Namenda, Memary, Aricept and Exelon. The combined market share of these four drugs was over 80% in the year 2016.
• Ebixa, Razadyne/Reminyl, Rivastach and Nootropil are the other popular drugs in the Alzheimer’s disease market.
• With the patent expiration of popular drugs the sales of the Alzheimer’s drugs have also declined. However, there are several pipeline drugs like Gantenerumab, Crenezumab and Aducanumab among others which are likely to hit the market during the period 2019 - 2020.
Global Alzheimer’s Disease Country Wise Analysis
• In the Alzheimer’s disease drugs market, the United States is the largest market.
• Japan is the second leading market for Alzheimer’s disease drugs market accounting for XXX% market share in 2016.
• China stands at the third spot in the global Alzheimer’s disease drugs market being followed by India with XXX% share in the same year.
• The EU5 countries together accounted for over 10% share of the global Alzheimer’s disease drugs market in 2016.
iGATE RESEARCH report titled “Global Alzheimer’s Disease Drugs Market, Regional Analysis & Forecast, Major Deals & Funding, and Pipeline Drugs Analysis to 2021” is a 189 Page report with 74 Figures and 14 Tables. This report provides a comprehensive assessment of the Alzheimer’s Disease Drugs Market, Alzheimer’s Disease Pipeline Drugs Market and Clinical Trials Analysis, Alzheimer’s Disease - Country Wise Drugs Market, Country Wise Alzheimer’s Disease Prevalence, Major Deals in Alzheimer’s Disease Drugs Market Landscape, Funding in Alzheimer’s Disease Drugs Research, Driving Factors and Challenges for Alzheimer’s Disease Drugs Market.
To view a detailed description and Table of Contents please visit: https://www.reportsworldwide.com/report/global-alzheimers-disease-drugs-market-regional-analysis--forecast-major-deals--funding-and-pipeline-drugs-analysis-to-2021
The Alzheimer’s Disease Drugs Market has been analyzed from 8 View Points:
1. Alzheimer’s Disease - Drugs Sales and Forecast
2. Alzheimer’s Disease - Pipeline Drugs Sales Forecast
3. Alzheimer’s Disease Drugs - Country Wise Market and Forecast
4. Alzheimer’s Disease - Country Wise Prevalence and Forecast
5. Alzheimer’s Disease – List of Pipeline Drugs in Various Phase of Development
6. Alzheimer’s Disease - Major Deals in Alzheimer’s Drugs Market
7. Alzheimer’s Disease - Funding in Alzheimer’s Disease Research
8. Alzheimer’s Disease Drugs Market – Driving Factors & Challenges
The Top 9 Alzheimer’s Disease Drugs covered in the report are as follows:
1. Exelon
2. Razadyne/Reminyl
3. Memary
4. Ebixa
5. Aricept
6. Rivastach
7. Namenda
8. Nootropil
9. Namzaric
The 3 Pipeline Alzheimer’s Disease Drugs covered in the report are as follows:
1. Gantenerumab
2. Crenezumab
3. Aducanumab
The 9 Countries Alzheimer’s Disease Drugs Market covered in the report are as follows:
1. United States
2. France
3. Germany
4. Italy
5. Spain
6. United Kingdom
7. Japan
8. China
9. India
List of Pipeline Alzheimer’s Disease Drugs in Various Phase of Development
1. Phase I
2. Phase II
3. Phase III
The Alzheimer’s Disease Drugs Major Deals covered in the report are as follows:
1. Strategic Alliance
2. Licensing Agreement
3. Collaboration Deals
4. Mergers and Acquisitions
Data Source
iGATE RESEARCH employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by iGATE Research dedicated team of qualified professionals with deep industry experience and expertise.
Research Methodologies
Primary Research Methodologies: Questionnaires, Surveys, Interviews with Individuals, Small Groups, Telephonic Interview, etc.
Secondary Research Methodologies: Printable and Non-printable sources, Newspaper, Magazine and Journal Content, Government and NGO Statistics, white Papers, Information on the Web, Information from Agencies Such as Industry Bodies, Companies Annual Report, Government Agencies, Libraries and Local Councils and a large number of Paid Databases.
To Get Sample Copy of Report please visit @ https://www.reportsworldwide.com/enquiry?report_id=41319
About ReportsWorldwide.com
ReportsWorldwide.com is a leading provider of global market intelligence reports and services. With research reports from top publishers, consulting and advisory firms, ReportsWorldwide.com offers instant online access to a growing database of expert insights on global industries, companies, products, geographies and trends.
Press Contact:
Abigail Crasto
Senior Vice President
101, Arch Street
Boston, MA 02110
US
Phone +1 (617) 398-4994
Fax +1 (617) 398-4995
abigail@reportsworldwide.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Alzheimer’s Disease Drugs Market, Regional Analysis & Forecast, Major Deals & Funding, and Pipeline Drugs Analysis to 2021 here
News-ID: 653135 • Views: …
More Releases from ReportsWorldwide
World Deep Brain Stimulation Market Top Segments, Key Players Revenue, Growth Ra …
The World Deep Brain Stimulation Market is estimated to represent a global market of USD 751.8 million by 2017 with growth rate of 18.2%. Deep brain stimulation (DBS) procedure is primarily used for the treatment of neuropsychiatric disorders such as mood disorder, dementia, anxiety and others. The procedure involve the use of neurotransmitter (brain pacemaker) that enables to transmit electric impulses to the specific target of brain cells. Increasing incidence…
New report explores the Gene Editing Market : Ushering The Next Breakthrough in …
Boston, MA
ReportsWorldwide has announced the addition of a new report title Gene Editing The Next Breakthrough in Regenerative Medicine to its growing collection of premium market research reports.
Genome editing is a type of genetic engineering in which DNA is replaced, inserted or deleted in a living organism's ggenome using engineered molecular scissors.
Believed to be one of the great biotechnology breakthroughs, gene editing is a powerful tool in pharmaceutical research that…
Global In-Building Wireless BTSController-based Small Cells Market Analysis and …
Boston, MA
ReportsWorldwide has announced the addition of a new report title Global In-Building Wireless BTSController-based Small Cells Market Analysis and Forecast, 2017-2021 to its growing collection of premium market research reports.
This report covers the leading in-building wireless enterprise BTS/controller-based small cells network equipment manufacturers:
• CommScope/Airvana
• Comba Telecom
• Ericsson
• Huawei Technologies
• Nokia
• SpiderCloud
• ZTE Corporation
This report covers the global market share for 2016 shipments as well as a forecast for 2017-2021.
To view a detailed description and Table of…
More Releases for Alzheimer
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is…
Anti-β-Alzheimer Therapies Market : Consumption, Revenue, Applications With Maj …
Alzheimer disease (AD) is a type of dementia that affects memory, thinking, language and behavior. Increasing age and high number of people suffering from Alzheimer's with age 65 and older are the major risk factors for progression of this disorder. It starts with mild symptoms and ends with severe brain damage in which individuals lose the ability to carry on a conversation and respond to their environment. According to Alzheimer…
Anti-β-Alzheimer Therapies That Cut Attacks Hailed As 'huge Deal'
Alzheimer disease (AD) is a type of dementia that affects memory, thinking, language and behavior. Increasing age and high number of people suffering from Alzheimer's with age 65 and older are the major risk factors for progression of this disorder. It starts with mild symptoms and ends with severe brain damage in which individuals lose the ability to carry on a conversation and respond to their environment. According to Alzheimer…
Alzheimer Diagnostic Tests Market - Medical Devices Pipeline Assessment, 2017 | …
"The Latest Research Report Alzheimer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
About Alzheimer Diagnostic Tests Market
GlobalData's Medical Devices sector report, Alzheimer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017" provides an overview of Alzheimer Diagnostic Tests currently in pipeline stage.
The report provides comprehensive information on the pipeline products with comparative analysis of…
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,…
Global Alzheimer Market Report: 2015 Edition | Now Available at Researchmoz.us
Researchmoz added Most up-to-date research on "Global Alzheimer Market Report: 2015 Edition" to its huge collection of research reports.
Alzheimer’s disease is defined as an advanced neurological disorder that increasingly deprives patients of their memory and ability to carry out daily activities. As it grows in a human brain, individuals are likely to practice difficulties in linguistic, agility and insight along with negative changes in the character and performance such as…
